Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia

Christine Manyando, Rhoda Mkandawire, Lwipa Puma, Moses Sinkala, Evans Mpabalwani, Eric Njunju, Melba Gomes, Isabela Ribeiro, Verena Walter, Mailis Virtanen, Raymond Schlienger, Marc Cousin, Miriam Chipimo, Frank M Sullivan, Christine Manyando, Rhoda Mkandawire, Lwipa Puma, Moses Sinkala, Evans Mpabalwani, Eric Njunju, Melba Gomes, Isabela Ribeiro, Verena Walter, Mailis Virtanen, Raymond Schlienger, Marc Cousin, Miriam Chipimo, Frank M Sullivan

Abstract

Background: Safety data regarding exposure to artemisinin-based combination therapy in pregnancy are limited. This prospective cohort study conducted in Zambia evaluated the safety of artemether-lumefantrine (AL) in pregnant women with malaria.

Methods: Pregnant women attending antenatal clinics were assigned to groups based on the drug used to treat their most recent malaria episode (AL vs. sulphadoxine-pyrimethamine, SP). Safety was assessed using standard and pregnancy-specific parameters. Post-delivery follow-up was six weeks for mothers and 12 months for live births. Primary outcome was perinatal mortality (stillbirth or neonatal death within seven days after birth).

Results: Data from 1,001 pregnant women (AL n = 495; SP n = 506) and 933 newborns (AL n = 466; SP n = 467) showed: perinatal mortality (AL 4.2%; SP 5.0%), comprised of early neonatal mortality (each group 2.3%), stillbirths (AL 1.9%; SP 2.7%); preterm deliveries (AL 14.1%; SP 17.4% of foetuses); and gestational age-adjusted low birth weight (AL 9.0%; SP 7.7%). Infant birth defect incidence was 1.8% AL and 1.6% SP, excluding umbilical hernia. Abortions prior to antenatal care could not be determined: abortion occurred in 4.5% of women treated with AL during their first trimester; none were reported in the 133 women exposed to SP and/or quinine during their first trimester. Overall development (including neurological assessment) was similar in both groups.

Conclusions: These data suggest that exposure to AL in pregnancy, including first trimester, is not associated with particular safety risks in terms of perinatal mortality, malformations, or developmental impairment. However, more data are required on AL use during the first trimester.

Figures

Figure 1
Figure 1
Participant flowchart. AL exposure group 9 pairs of twins; SP exposure group 7 pairs of twins.

References

    1. WHO. Malaria During Pregnancy, The Africa Malaria Report 2003. pp. 38–43.
    1. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64(1-2 Suppl):28–35.
    1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104. doi: 10.1016/S1473-3099(07)70021-X.
    1. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999;353:632–636. doi: 10.1016/S0140-6736(98)07318-8.
    1. Mbaye A, Richardson K, Balajo B, Dunyo S, Shulman C, Milligan P, Greenwood B, Walraven G. A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. Trop Med Int Health. 2006;11:992–1002. doi: 10.1111/j.1365-3156.2006.01649.x.
    1. WHO. Guidelines for the treatment of malaria. 2010.
    1. WHO. Assessment of the safety of artemisinin compounds in pregnancy. 2007.
    1. McGready R, Cho T, Keo NK, Thwai KL, Villegas L, Looareesuwan S, White NJ, Nosten F. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis. 2001;33:2009–2016. doi: 10.1086/324349.
    1. Li GQ, Guo XB, Fu LC, Jian HX, Wang XH. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg. 1994;88(Suppl 1):S5–S6. doi: 10.1016/0035-9203(94)90460-X.
    1. Wang TY. Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant women. J Trad Chinese Med. 1989;9:28–30.
    1. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, Wüstefeld K, Barends M, Laochan N, Keereecharoen L, Lindegardh N, Singhasivanon P, White NJ, Nosten F. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5:e253. doi: 10.1371/journal.pmed.0050253.
    1. White TEK, Bushdid PB, Ritter S, Laffan SB, Clark RL. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res. 2006;77:413–429. doi: 10.1002/bdrb.20092.
    1. Clark RL, Kumemura M, Makori, Nakata Y, Bernard F, Harrell A, White TEK, Arima A. Artesunate: developmental toxicity in monkeys. Birth Defects Res. 2006;76:329. [Abstract]
    1. Sipilanyambe N, Simon JL, Chanda P, Olumese P, Snow RW, Hamer DH. From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia. Malar J. 2008;7:25. doi: 10.1186/1475-2875-7-25.
    1. Munjanja SP, Masona D. Zimbabwean birth weight for gestation standards. Central African J Med. 1990;36:144–147.
    1. Dubowitz LMS, Dubowitz V, Goldberg C. Clinical assessment of gestational age in the newborn infant. J Pediatr. 1970;77:1–10. doi: 10.1016/S0022-3476(70)80038-5.
    1. Haataja L, McGready R, Arunjerdja R, Simpson JE, Mercuri E, Nosten F, Dubowitz L. A new approach for neurological evaluation of infants in resource-poor settings. Ann Trop Paediatr. 2002;22:355–368. doi: 10.1179/027249302125002029.
    1. Rubin DE. Multiple imputation after 18+ years. J Am Statist Assoc. 1996;19:473–489. doi: 10.2307/2291635.
    1. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med. 1998;17:2267–2281.
    1. Schulz KF, Cates W Jr, O'Mara PR. Pregnancy loss, infant death and suffering: legacy of syphilis and gonorrhoea in Africa. Genitourin Med. 1987;63:322.
    1. Meier DE, OlaOlorun DA, Omodele RA, Nkor SK, Tarpley JL. Incidence of umbilical hernia in African children: redefinition of "normal" and re-evaluation of indications for repair. World J Surg. 2001;25:645–648. doi: 10.1007/s002680020072.
    1. Ebomoyi E, Parakoyi DB, Omonisi MK. Nutritional status and umbilical hernia in Nigerian school children of different ethnic groups. J Natl Med Assoc. 1991;83:905–908.
    1. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar J. 2007;6:15. doi: 10.1186/1475-2875-6-15.
    1. Dellicour S, ter Kuile FO, Stergachis A. Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med. 2008;5:e187. doi: 10.1371/journal.pmed.0050187.
    1. McDermott JM, Wirima JJ, Steketee RW, Breman JG, Heymann DL. The effect of placental malaria infection on perinatal mortality in rural Malawi. Am J Trop Med Hyg. 1996;55:61–65.
    1. Kumala T, Vaahtera M, Ndekha M, Koivisto AM, Cullinan T, Salin ML, Ashorn P. The importance of preterm births for peri- and neonatal mortality in rural Malawi. Paediatr Perinatal Epidemiol. 2000;14:219–226. doi: 10.1046/j.1365-3016.2000.00270.x.
    1. van Geertruyden JP, Thomas F, Erhart A, D'Alessandro U. The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg. 2004;71:35–40.
    1. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 1997;315:32–34.
    1. Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, Van Allen M, Aarons JH, Metzger B, Bieber FR, Knopp RH, Holmes LB. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. NEJM. 1988;319:1617–1623. doi: 10.1056/NEJM198812223192501.
    1. China Cooperative Research Group on Qinghaosu and its Derivatives as Anti-malarials. Studies on the toxicity of Qinghaosu and its derivatives. J Tradit Chin Med. 1982;2:31–36.
    1. Clarke RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol. 2009.
    1. Simpkiss M, Lowe A. Congenital abnormalities in the African newborn. Arch Child Dis. 1961. pp. 404–406.
    1. Kromberg JG, Jenkins T. Common birth defects in South African Blacks. S Afr Med J. 1982;16:599–602.
    1. van Regemorter N, Dodion J, Druart C, Hayez F, Vamos E, Flament-Durand J, Perlmutter-Cremer N, Rodesch F. Congenital malformations in 10,000 consecutive births in a university hospital: need for genetic counseling and prenatal diagnosis. J Pediatr. 1984;104:386–390. doi: 10.1016/S0022-3476(84)81100-2.
    1. Adam I, Ali DM, Abdalla MA. Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg. 2006;100:632–635. doi: 10.1016/j.trstmh.2005.09.019.
    1. Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg. 2001;95:424–428. doi: 10.1016/S0035-9203(01)90204-4.
    1. Ward SA, Sevene EJP, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7:136–144. doi: 10.1016/S1473-3099(07)70025-7.
    1. U.S Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: establishing pregnancy exposure registries. 2002.
    1. European Medicines Agency. Guideline on exposure to medicinal products during pregnancy: need for post-authorisation data. 2005.
    1. Dawodu AH, Effiong CE. Assessment of gestational age in full term and preterm African newborn infants. Nig J Pediat. 1977;4:1–5.
    1. Sayed AR, Bourne D, Pattinson R, Nixon J, Henderson B. Decline in the prevalence of neural tube defects following folic acid fortification and its cost-benefit in South Africa. Birth Defects Res. 2008;82:211–216. doi: 10.1002/bdra.20442.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅